Q-omics provides the consensus-scored S100A4 profile across patient tissues and cancer cell-line models. S100A4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, S100A4 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, S100A4 protein abundance shows 27,697 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where S100A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A4 survival associations across molecular data types. S100A4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A4 RNA expression–survival associations across cancer types. High S100A4 expression shows unfavorable associations in UVM, LGG and LAML, but favorable associations in HNSC, BLCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for S100A4 RNA expression.
This table summarizes S100A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for S100A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A4 shows lower tumor expression in KICH, LUSC, LUAD and BRCA and higher tumor expression in CHOL and LIHC. The KICH box plot shows higher S100A4 RNA expression in normal versus tumor tissue (log2 FC = −3.534, t-test p < 0.001).
This table shows molecular features associated with S100A4 in patient tissues and cancer cell lines. In patient samples, S100A4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, S100A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
